of a
leader
Hifas Biologics is a biotech company focused on early drug discovery based on fungi as a natural source of pharmaceuticals.
Our key features
Bridging the gap between nature and pharmaceutical, exploring the therapeutic potential of fungi
Drug Discovery and development targeting diseases with high unmet medical need and excellent market potential
Focus on clinically validated targets reducing development risks
Novel and differentiated compounds with strong IP through medicinal chemistry
Where we come from
Hifas Biologics is the first company incorporated from Hifas Innovation Hub, the venture builder of Hifas da Terra, a biotechnology R&D centre focused on the development of nutraceuticals from medicinal mushrooms.
Excellence Team
Hifas Biologics is composed of a highly qualified multidisciplinary team that brings diverse expertise and a shared passion for pushing the boundaries of science and improving human health through the discovery of new drugs derived from fungi.
Leadership team
Scienfific advisory comittee
Support team
Claudia Fernández Mariña
Diego Rubianes Fariña
Open Innovation & Projects
Hifas Biologics was born with a focus on open innovation, collaborating with international leaders and experts in pharmacological research to ensure agility in our development pipelines and maximum effectiveness in the products we develop. Therefore, the development of new partnerships is an essential part of Hifas Biologics' philosophy. We are working with some of the top academic, financial, and industrial institutions at the national level to drive the different stages of new antibiotic development. Click to learn more from our collaborators.
Partners and collaborators
ABAC Therapeutics is a pharmaceutical company committed to finding innovative therapeutic solutions to protect the lives of patients infected with resistant bacteria. It has its own drug discovery platform called PNAS, a highly scalable multiplex platform designed to reduce attrition rates of anti-infective drugs, based on technical risk management and cost reduction in development.
Customized solutions for preclinical validation of microfluidic devices. BFlow offers microfluidic solutions through the custom design and laser-based manufacturing of a chip with microchannels that enable cellular cultivation and application of flow simulation.
The BioFarma Research Group and its Drug Screening and Pharmacogenomics Platform, Innopharma (University of Santiago de Compostela), are coordinated by Mabel Loza. Innopharma is one of the high-capacity platforms within the European Research Infrastructure Consortium (ERIC) EU-OPENSCREEN. They have extensive experience in early drug discovery and have participated in the discovery of 17 new chemical entities that have reached clinical trials through public-private partnerships.
The BioFarma Research Group and its Drug Screening and Pharmacogenomics Platform, Innopharma (University of Santiago de Compostela), are coordinated by Mabel Loza. Innopharma is one of the high-capacity platforms within the European Research Infrastructure Consortium (ERIC) EU-OPENSCREEN. They have extensive experience in early drug discovery and have participated in the discovery of 17 new chemical entities that have reached clinical trials through public-private partnerships.
AMSLab is one of the leading European laboratories in quality control across various sectors. They provide high-quality analytical solutions for the chemical, pharmaceutical, and biopharmaceutical industries. AMSLab offers customized services to clients, including identification, characterization, and quantification of impurities and unknown substances in small molecules, as well as analysis and characterization of proteins, peptides, and monoclonal antibodies (mAbs).
Plexus Tech is a technology company specialized in IT services and products, founded on the talent and capabilities of a team with over 2,000 professionals. They focus on developing technological products and services that enhance the lives of individuals, companies, and institutions. With a model based on proximity, speed, and flexibility, Plexus Tech aims to deliver innovative solutions to meet the needs of their clients.
R&I Programmes
Period 01/2023-12/2024
Researcher: José Manuel Pérez de la Lastra (Instituto de Productos Naturales y Agrobiología (IPNA))
The intention is to thoroughly explore defensins and their derivatives (DLPs – defensin-like peptides) produced by basidiomycete fungi. The structure, function, potential, and diversity in pathogen control will be analyzed.
